Ranbaxy Issues Voluntary Nationwide Recall of 41 Lots of Atorvastatin Calcium Tablets Due to Potenti
date:Nov 29, 2012
ers should immediately contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online:www.fda.gov/medwatch/report.htm
Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getform
5/20 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/29 21:21